Low-molecular-weight heparin and early neurologic deterioration in acute stroke caused by large artery occlusive disease

Archives of Neurology

Volumn 69, Issue 11, 2012, Pages 1454-1460

  Wang, Qiaoshu ^a   Chen, Christopher ^c   Chen, Xiang Yan ^b   Han, Jing Hao ^b   Soo, Yannie ^b   Leung, Thomas W ^b   Mok, Vincent ^b   Wong, Ka Sing Lawrence ^b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; LIVER ENZYME; LOW MOLECULAR WEIGHT HEPARIN;

ADULT; AGED; ARTERY OCCLUSION; ARTICLE; BARTHEL INDEX; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; ESOPHAGUS ULCER; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; LARGE ARTERY OCCLUSIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROLOGIC DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RANKIN SCALE; RISK FACTOR; RISK REDUCTION;

AGED; ANTICOAGULANTS; ARTERIAL OCCLUSIVE DISEASES; ASPIRIN; CHI-SQUARE DISTRIBUTION; DRUG ADMINISTRATION ROUTES; FEMALE; FOLLOW-UP STUDIES; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; MIDDLE AGED; NERVOUS SYSTEM DISEASES; SEVERITY OF ILLNESS INDEX; STROKE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84868544081     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2012.1633     Document Type: Article

References (30)

1. Lovett JK, Coull AJ, Rothwell PM. Early risk of recurrence by subtype of ischemic stroke in population-based incidence studies. Neurology. 2004;62(4):569-573. (Pubitemid 38252797)
2. Mazighi M, Tanasescu R, Ducrocq X, et al. Prospective study of symptomatic atherothrombotic intracranial stenoses: the GESICA study. Neurology. 2006;66(8):1187-1191. (Pubitemid 43739702)
3. Caplan LR, Gorelick PB, Hier DB. Race, sex and occlusive cerebrovascular disease: a review. Stroke. 1986;17(4):648-655. (Pubitemid 16066533)
4. Sacco RL, Kargman DE, Gu Q, Zamanillo MC. Race-ethnicity and determinants of intracranial atherosclerotic cerebral infarction: the Northern Manhattan Stroke Study. Stroke. 1995;26(1):14-20.
5. Li H, Wong KS. Racial distribution of intracranial and extracranial atherosclerosis. J Clin Neurosci. 2003;10(1):30-34. (Pubitemid 35453243)
6. Thijs VN, Albers GW. Symptomatic intracranial atherosclerosis: outcome of patients who fail antithrombotic therapy. Neurology. 2000;55(4):490-497. (Pubitemid 30647243)
7. CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet. 1997;349(9066):1641-1649.
8. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet. 1997;349(9065):1569-1581.
9. Sacco RL, Diener HC, Yusuf S, et al; PRoFESS Study Group. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med. 2008;359(12):1238-1251.
10. The Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) Study Group. Prognosis of patients with symptomatic vertebral or basilar artery stenosis. Stroke. 1998;29(7):1389-1392.
11. Chimowitz MI, Lynn MJ, Howlett-Smith H, et al Warfarin-Aspirin Symptomatic Intracranial Disease Trial Investigators. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med. 2005;352(13):1305-1316.
12. Berge E, Abdelnoor M, Nakstad PH, Sandset PM. Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial. Lancet. 2000;355(9211):1205-1210. (Pubitemid 30184528)
13. Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial. JAMA. 1998;279(16):1265-1272.
14. Bath PM, Lindenstrom E, Boysen G, et al. Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial. Lancet. 2001;358(9283):702-710. (Pubitemid 32823398)
15. Wong KS, Chen C, Ng PW, et al FISS-tris Study Investigators. Low-molecular-weight heparin compared with aspirin for the treatment of acute ischaemic stroke in Asian patients with large artery occlusive disease: a randomised study. Lancet Neurol. 2007;6(5):407-413. (Pubitemid 46551851)
16. Bath PM. Low molecular weight heparin in acute stroke. Expert Opin Investig Drugs. 1998;7(8):1323-1330. (Pubitemid 28359496)
17. Wong KS, Lam WW, Liang E, Huang YN, Chan YL, Kay R. Variability of magnetic resonance angiography and computed tomography angiography in grading middle cerebral artery stenosis. Stroke. 1996;27(6):1084-1087. (Pubitemid 26177610)
18. Wong KS, Li H, Chan YL, et al. Use of transcranial Doppler ultrasound to predict outcome in patients with intracranial large-artery occlusive disease. Stroke. 2000;31(11):2641-2647.
19. Weimar C, Mieck T, Buchthal J, Ehrenfeld CE, Schmid E, Diener HC; German Stroke Study Collaboration. Neurologic worsening during the acute phase of ischemic stroke. Arch Neurol. 2005;62(3):393-397. (Pubitemid 40349474)
20. Awadh M, MacDougall N, Santosh C, Teasdale E, Baird T, Muir KW. Early recurrent ischemic stroke complicating intravenous thrombolysis for stroke: incidence and association with atrial fibrillation. Stroke. 2010;41(9):1990- 1995.
21. Fiorelli M, Bastianello S, von Kummer R, et al. Hemorrhagic transformation within 36 hours of a cerebral infarct: relationships with early clinical deterioration and 3-month outcome in the European Cooperative Acute Stroke Study I (ECASS I) cohort. Stroke. 1999;30(11):2280-2284. (Pubitemid 29517722)
22. Hommel M; FISS-bis Investigators Group. Fraxiparine in Ischemic Stroke Study (FISS bis). Cerebrovasc Dis. 1998;8(suppl 4):19.
23. Serena J, Rodríguez-Yáñez M, Castellanos M. Deterioration in acute ischemic stroke as the target for neuroprotection. Cerebrovasc Dis. 2006;21(suppl 2):80-88.
24. Rothwell PM, Giles MF, Chandratheva A, et al; Early use of Existing Preventive Strategies for Stroke (EXPRESS) study. Effect of urgent treatment of transient ischaemic attack and minor stroke on early recurrent stroke (EXPRESS study): a prospective population-based sequential comparison [published correction appears in Lancet. 2008;371(9610):386]. Lancet. 2007;370(9596):1432- 1442. (Pubitemid 47576154)
25. Wong KS, Gao S, Chan YL, et al. Mechanisms of acute cerebral infarctions in patients with middle cerebral artery stenosis: a diffusion-weighted imaging and microemboli monitoring study. Ann Neurol. 2002;52(1):74-81. (Pubitemid 34693746)
26. Wong KS, Chen C, Fu J, et al; CLAIR study investigators. Clopidogrel plus aspirin versus aspirin alone for reducing embolisation in patients with acute symptomatic cerebral or carotid artery stenosis (CLAIR study): a randomised, open-label, blinded-endpoint trial. Lancet Neurol. 2010;9(5):489-497.
27. Bendszus M, Koltzenburg M, Bartsch AJ, et al. Heparin and air filters reduce embolic events caused by intra-arterial cerebral angiography: a prospective, randomized trial. Circulation. 2004;110(15):2210-2215. (Pubitemid 39372503)
28. Hao Q, Chang HM, Wong MC, Wong KS, Chen C. Frequency of microemboli signal in stroke patients treated with low molecular weight heparin or aspirin. J Neuroimaging. 2010;20(2):118-121.
29. Caplan LR. Resolved: heparin may be useful in selected patients with brain ischemia. Stroke. 2003;34(1):230-231.
30. Tei H, Uchiyama S, Usui T, Ohara K. Diffusion-weighted ASPECTS as an independent marker for predicting functional outcome. J Neurol. 2011;258(4):559-565.